Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ (IBIS-II DCIS)
International Breast Cancer Intervention Study II (IBIS-II) (DCIS)
Sponsor: Cancer Research UK
This PHASE3 trial investigates Breast Cancer and is currently completed. Cancer Research UK leads this study, which shows 11 recorded versions since 2003 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Sep 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Research UK
- Queen Mary University of London
For direct contact, visit the study record on ClinicalTrials.gov .